Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $46.4 million.

  • Tg Therapeutics' Cash from Investing Activities rose 59671.09% to $46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year increase of 17344.22%. This contributed to the annual value of -$1.0 million for FY2024, which is 9795.46% up from last year.
  • Tg Therapeutics' Cash from Investing Activities amounted to $46.4 million in Q3 2025, which was up 59671.09% from -$4.0 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Cash from Investing Activities peaked at $46.4 million during Q3 2025, and registered a low of -$44.8 million during Q4 2023.
  • Over the past 5 years, Tg Therapeutics' median Cash from Investing Activities value was -$2.5 million (recorded in 2021), while the average stood at -$2.2 million.
  • As far as peak fluctuations go, Tg Therapeutics' Cash from Investing Activities crashed by 839630.35% in 2022, and later soared by 59671.09% in 2025.
  • Over the past 5 years, Tg Therapeutics' Cash from Investing Activities (Quarter) stood at $3.3 million in 2021, then surged by 394.8% to $16.3 million in 2022, then tumbled by 375.09% to -$44.8 million in 2023, then skyrocketed by 135.28% to $15.8 million in 2024, then skyrocketed by 193.66% to $46.4 million in 2025.
  • Its Cash from Investing Activities was $46.4 million in Q3 2025, compared to -$4.0 million in Q2 2025 and -$12.9 million in Q1 2025.